Showing results (1-10 of 509) with videos related to
Sort By:
Pageof 51
Medizinische Klinik (Munich, Germany : 1983)|January 5, 2002
[Artificial sweeteners--are they potentially carcinogenic?]M R Weihrauch, V Diehl, H BohlenAnnals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2004
Artificial sweeteners--do they bear a carcinogenic risk?M R Weihrauch, V DiehlAnnals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1996
Report on the workshop biology of the Third International Symposium on Hodgkin's Lymphoma in Cologne 1995J Wolf, H Bohlen, V DiehlBlood|November 8, 2001
Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin diseaseM R Weihrauch, D Re, K Scheidhauer, et al.Journal of Immunological Methods|January 20, 1998
Single-step purification of bispecific monoclonal antibodies for immunotherapeutic use by hydrophobic interaction chromatographyO Manzke, H Tesch, V Diehl, et al.Annals of Hematology|May 10, 2000
Poor clinical outcome of patients with Hodgkin's disease and elevated interleukin-10 serum levels. Clinical significance of interleukin-10 serum levels for Hodgkin's diseaseH Bohlen, M Kessler, M Sextro, et al.Cancer Immunology, Immunotherapy : CII|January 22, 1998
CD3 x CD19 bispecific antibodies and CD28 costimulation for locoregional treatment of low-malignancy non-Hodgkin's lymphomaO Manzke, S Titzer, H Tesch, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 1995
Serum cytokine levels correlate with clinical parameters in Hodgkin's diseaseM Gorschlüter, H Bohlen, D Hasenclever, et al.International Journal of Cancer|March 17, 2001
Locoregional treatment of low-grade B-cell lymphoma with CD3xCD19 bispecific antibodies and CD28 costimulation. II. Assessment of cellular immune responsesO Manzke, H Tesch, J Lorenzen, et al.Bone Marrow Transplantation|August 10, 2000
Treatment of patients with malignant lymphomas with monoclonal antibodiesH Tesch, A Engert, O Manzke, et al.Pageof 51